Literature DB >> 8834442

Matrix metalloproteinase activity in human intrahepatic biliary epithelial cell lines from patients with autosomal dominant polycystic kidney disease.

S L Murray1, S A Grubman, R D Perrone, M Rojkind, E Moy, D W Lee, D M Jefferson.   

Abstract

Hepatic cysts derived from intrahepatic bile ducts are the most common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). Cyst enlargement involves cell proliferation, fluid secretion into cysts, and alterations in extracellular matrix. To study hepatic cyst formation, continuous cell lines from human normal intrahepatic biliary epithelium (IBE) and ADPKD liver cyst-derived epithelium (LCDE) were developed. Because matrix degradation and remodeling are important for cyst formation and growth, we investigated matrix modifying enzymes expressed in IBE and LCDE cell lines. Gelatin substrate zymography showed that two matrix degrading activities with characteristics of matrix metalloproteinases are secreted from these cell lines. Western immunoblotting suggests that these activities correspond to the 72 kDa (Gelatinase A) and 92 kDa (Gelatinase B) type IV collagenases. Although the level of Gelatinase A activity is comparable in both IBE and LCDE cell lines, Gelatinase B activity is substantially increased in LCDE lines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834442     DOI: 10.3109/03008209609028882

Source DB:  PubMed          Journal:  Connect Tissue Res        ISSN: 0300-8207            Impact factor:   3.417


  7 in total

Review 1.  Isolated polycystic liver disease.

Authors:  Qi Qian
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

Review 2.  Polycystic Liver Disease: Pathophysiology, Diagnosis and Treatment.

Authors:  Luiz Fernando Norcia; Erika Mayumi Watanabe; Pedro Tadao Hamamoto Filho; Claudia Nishida Hasimoto; Leonardo Pelafsky; Walmar Kerche de Oliveira; Ligia Yukie Sassaki
Journal:  Hepat Med       Date:  2022-09-29

3.  Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.

Authors:  Aura D Urribarri; Patricia Munoz-Garrido; María J Perugorria; Oihane Erice; Maite Merino-Azpitarte; Ander Arbelaiz; Elisa Lozano; Elizabeth Hijona; Raúl Jiménez-Agüero; Maite G Fernandez-Barrena; Juan P Jimeno; Marco Marzioni; Jose J G Marin; Tatyana V Masyuk; Nicholas F LaRusso; Jesús Prieto; Luis Bujanda; Jesús M Banales
Journal:  Gut       Date:  2014-01-16       Impact factor: 23.059

4.  Polycystic disease caused by deficiency in xylosyltransferase 2, an initiating enzyme of glycosaminoglycan biosynthesis.

Authors:  Eduard Condac; Robert Silasi-Mansat; Stanley Kosanke; Trenton Schoeb; Rheal Towner; Florea Lupu; Richard D Cummings; Myron E Hinsdale
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

5.  Identification of MMP1 as a novel risk factor for intracranial aneurysms in ADPKD using iPSC models.

Authors:  Tomonaga Ameku; Daisuke Taura; Masakatsu Sone; Tomohiro Numata; Masahiro Nakamura; Fumihiko Shiota; Taro Toyoda; Satoshi Matsui; Toshikazu Araoka; Tetsuhiko Yasuno; Shin-Ichi Mae; Hatasu Kobayashi; Naoya Kondo; Fumiyo Kitaoka; Naoki Amano; Sayaka Arai; Tomoko Ichisaka; Norio Matsuura; Sumiko Inoue; Takuya Yamamoto; Kazutoshi Takahashi; Isao Asaka; Yasuhiro Yamada; Yoshifumi Ubara; Eri Muso; Atsushi Fukatsu; Akira Watanabe; Yasunori Sato; Tatsutoshi Nakahata; Yasuo Mori; Akio Koizumi; Kazuwa Nakao; Shinya Yamanaka; Kenji Osafune
Journal:  Sci Rep       Date:  2016-07-15       Impact factor: 4.379

6.  Quantitative Proteomic Study Unmasks Fibrinogen Pathway in Polycystic Liver Disease.

Authors:  Adrian Cordido; Marta Vizoso-Gonzalez; Laura Nuñez-Gonzalez; Alberto Molares-Vila; Maria Del Pilar Chantada-Vazquez; Susana B Bravo; Miguel A Garcia-Gonzalez
Journal:  Biomedicines       Date:  2022-01-27

Review 7.  Reactive Oxygen Species and Redox Signaling in Chronic Kidney Disease.

Authors:  Maria V Irazabal; Vicente E Torres
Journal:  Cells       Date:  2020-05-28       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.